Gear Up for Axis Capital (AXS) Q4 Earnings: Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2217008/gear-up-for-axis-capital-axs-q4-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2217008
Jan 29, 2024 - Besides Wall Street's top -and-bottom-line estimates for Axis Capital (AXS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
https://www.zacks.com/stock/news/2217270/bd-bdx-gears-up-for-q1-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217270
Jan 29, 2024 - Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.
0
Markets Stroll Higher Ahead of Key Data; SMCI, FFIV, WHR Beat
https://www.zacks.com/stock/news/2217484/markets-stroll-higher-ahead-of-key-data-smci-ffiv-whr-beat?cid=CS-ZC-FT-ahead_of_wall_street-2217484
Jan 29, 2024 - A sixth record closing high for the S&P 500 just this month/year alone ought to give a good impression of where the market's collective head is at presently.
0
Home Prices Decreased in November
https://www.zacks.com/stock/news/2218065/home-prices-decreased-in-november?cid=CS-ZC-FT-economic_highlights-2218065
Jan 30, 2024 - Home Prices Decreased in November
0
GM Up on Q4 Beat & Raise; UPS, Pfizer Mixed
https://www.zacks.com/stock/news/2218048/gm-up-on-q4-beat-raise-ups-pfizer-mixed?cid=CS-ZC-FT-ahead_of_wall_street-2218048
Jan 30, 2024 - Aside from a cavalcade of earnings, Case-Shiller came in lower month over month and JOLTS are out after the open.
0
Calix (CALX) Q4 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2218228/calix-calx-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2218228
Jan 30, 2024 - Calix's (CALX) top line benefits from growth in the cloud and managed services for Broadband Service Providers in the fourth quarter.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test
https://www.zacks.com/stock/news/2218936/bd-s-bdx-tie-up-to-offer-ai-based-digital-system-for-pap-test?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218936
Jan 31, 2024 - BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.
0
NVR Q4 Earnings Beat, Homebuilding Revenues Lag, Orders Up 25%
https://www.zacks.com/stock/news/2218931/nvr-q4-earnings-beat-homebuilding-revenues-lag-orders-up-25?cid=CS-ZC-FT-analyst_blog|earnings_article-2218931
Jan 31, 2024 - NVR's fourth-quarter 2023 results are hurt by higher rates during the period compared to a year ago. Yet, improved demand trends led to higher orders.
0
4 GARP Stocks to Scoop up for Maximum Returns
https://www.zacks.com/stock/news/2218861/4-garp-stocks-to-scoop-up-for-maximum-returns?cid=CS-ZC-FT-analyst_blog|rw-2218861
Jan 31, 2024 - Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NRG, DRI, ALSN and IQV are some stocks that hold promise.
0